TICKERNERD
Menu
REVBREVBHealthcare · Biotechnology

REVB Stock Forecast: Revelation Biosciences, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.10
+0.92% on the day

The 1 Wall Street analysts covering Revelation Biosciences, Inc. hold a median 12-month price target of $18 — +1513.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.3M
Ticker Nerd rank
8 / 100
Median analyst target
$18
Analysts covering
1
Total return, dividends reinvested
1W
−4.3%
1M
+3.8%
YTD
−65.6%
1Y
−90.6%
From 52W high
−90.4%
From 52W low
+15.8%
$1
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

REVB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Revelation Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Volatility
54
Accruals
46
Revisions
30
Growth
25
Quality
12
Momentum
7
Issuance
6
Value
2

Size (97): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

REVB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REVB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26REVBHigh $20Median $18Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $16Median $18High $20

The green dot is the last close — the median target sits +1513.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Feb 2023Roth MKMMaintainsBuy$5.00 → $15
17 Feb 2022Roth CapitalInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REVB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

REVB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Revelation Biosciences, Inc. (REVB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
0.6×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−154.8%

Higher than 9% of US stocks

Return on assets
−78.7%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

REVB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REVBRevelation Biosciences, Inc.$4.3M
8
TCRTAlaunos Therapeutics, Inc.$4.3M
31
SILOSilo Pharma, Inc.$4.2M
24
MBIOMustang Bio, Inc.$4.4M
13
JAGXJaguar Health, Inc.$4.5M
57
GLMDGalmed Pharmaceuticals Ltd.$4.5M
19
HCWBHCW Biologics Inc.$4.0M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Revelation Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REVB news & analysis

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

Business Wire · 19 Aug 2026positive

Revelation Biosciences announced it has selected Avance Clinical, a full-service contract research organization with global operations, as the CRO for its Phase 2/3 adaptive-design TITAN study evaluating Gemini in patients with acute kidney injury.

Why it matters — REVB watchers would care because selecting a CRO is a key step toward advancing the TITAN study, a major clinical milestone for the company's Gemini candidate.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Accesswire · 6 Aug 2026positive

Revelation Biosciences reported financial results for the three and six months ended June 30, 2026, and highlighted progress on its Phase 2/3 clinical trial for Gemini in acute kidney injury, including the formation of an Acute Kidney Injury Advisory Board and startup activities.

Why it matters — A REVB watcher would care because the company is advancing its pivotal Phase 2/3 study for Gemini, which an independent market assessment suggested addresses a $94 billion total addressable market.

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Accesswire · 3 Aug 2026positive

Revelation Biosciences announced results of an independent market assessment identifying a potential $94 billion total addressable market for Gemini in treating Stage 2 and Stage 3 Acute Kidney Injury, confirming an unmet medical need. The assessment noted that AKI affects more than 10% of hospitalized patients and more than 50% of intensive care unit patients, per publicly available data.

Why it matters — The assessment signals a large potential commercial opportunity for Revelation's lead candidate Gemini and reinforces the size of the unmet medical need REVB is targeting.

FAQ

Frequently asked questions about REVB stock

What is the REVB stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Revelation Biosciences, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REVB stock a buy right now?

Of the 1 analysts covering Revelation Biosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revelation Biosciences, Inc. 8 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REVB?

As at 22 Aug 2026, Revelation Biosciences, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will REVB stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1513.6% from the last close, and Ticker Nerd's factor model ranks Revelation Biosciences, Inc. 8 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REVB stock forecast for 2030?

No analyst covering Revelation Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REVB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $20 over the next 12 months.

How has REVB stock performed over the past year?

Revelation Biosciences, Inc. returned -90.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Revelation Biosciences, Inc. do?

Revelation Biosciences Inc. is a biotechnology company focused on developing diagnostic and therapeutic products to address respiratory and infectious diseases.

What is the latest news on REVB?

The most recent item we track (Business Wire, 19 Aug 2026): "Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study". Revelation Biosciences announced it has selected Avance Clinical, a full-service contract research organization with global operations, as the CRO for its Phase 2/3 adaptive-design TITAN study evaluating Gemini in patients with acute kidney injury.

Company

About Revelation Biosciences, Inc.

Revelation Biosciences Inc. is a biotechnology company focused on developing diagnostic and therapeutic products to address respiratory and infectious diseases. Their primary function is to innovate in the field of healthcare with novel solutions that can detect and combat prevalent health threats. Notably, Revelation Biosciences is involved in creating point-of-care diagnostic tests that aim to quickly and efficiently identify infections, enabling timely and informed medical decisions. The company also pursues therapeutic development to improve treatment outcomes for patients suffering from respiratory ailments. Within the financial market, Revelation Biosciences contributes to the healthcare and biotech sectors, representing the intersection of technology and medicine to address critical health challenges. With a commitment to research and development, Revelation Biosciences is a key player in improving diagnostic and therapeutic approaches, thus enhancing healthcare delivery and patient care globally.

CEO Mr. James M. Rolke · 8 employees · United States · https://www.revbiosciences.com